Efficacy of Yasmin in premenstrual symptoms
- 127 Downloads
To evaluate the effect of oral contraception formulation with drospirenone (Yasmin) on premenstrual symptoms.
Materials and methods
An open-label non-comparative clinical trial was conducted. One hundred women who desired oral contraception for at least 6 months were recruited. The subjects received a blister pack which contained 21 tablets of 3 mg drospirenone/30 μg ethinyl estradiol for the first four cycles (1 cycle = 28 days). Cycle-5 and -6 blister packs were dispensed during the next visit in cycle 4. The subjects were evaluated on menstruation-related symptoms by using the women’s health assessment questionnaire (WHAQ) at baseline and at each follow-up visit for three phases of their menstrual cycle. The measured outcome was the mean score changes from baseline to cycle 6 of WHAQ categories.
Of the total 100 subjects, 92 (92%) completed the study. At the premenstrual phase, a significant decrease was seen from baseline to cycle 6 in the mean WHAQ scores for impaired concentration, water retention, negative effect, increased appetite, feeling of well-being and undesirable hair change. At the menstrual phase, a significant decrease was seen from baseline to cycle 6 regarding the mean WHAQ scores for impaired concentration, negative effect, feeling of well-being, and undesirable hair change. At the postmenstrual phase, significant changes were consistently observed regarding the feeling of well-being and undesirable hair change.
Oral contraception formulation with drospirenone (Yasmin) has an ameliorating effect on premenstrual symptoms. This oral contraception may have a role in women who are looking forward to use contraception and also suffer from premenstrual symptoms.
KeywordsOral contraception Drospirenone Premenstrual symptoms WHAQ score
- 7.Daugherly JE (1998) Treatment strategies for premenstrual syndrome. Am Fam Physician 58:183–192Google Scholar
- 9.Endrikat J, Muller U, Dusterberg B (1997) A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. Contraception 55:131–137PubMedCrossRefGoogle Scholar
- 11.Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R (2000) A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 5:124–134PubMedCrossRefGoogle Scholar
- 14.Moos RH (1991) Menstrual distress questionnaire manual. Western Psychological Service, Los AngelesGoogle Scholar
- 19.Severino SK, Moline ML (1989) Premenstrual syndrome: a clinician’s guide. Guilford press, New YorkGoogle Scholar
- 21.World Health Organization (WHO) (1996). Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use methods. World Health Organization, GenevaGoogle Scholar
- 22.Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A (2005) Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106:492–501Google Scholar